Renaissance Group LLC Reduces Holdings in Cencora, Inc. $COR

Renaissance Group LLC reduced its position in Cencora, Inc. (NYSE:COR) by 18.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,081 shares of the company’s stock after selling 900 shares during the quarter. Renaissance Group LLC’s holdings in Cencora were worth $1,224,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Private Advisor Group LLC boosted its position in Cencora by 9.2% during the first quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock worth $1,890,000 after acquiring an additional 572 shares during the last quarter. J.W. Cole Advisors Inc. lifted its stake in Cencora by 49.3% in the 1st quarter. J.W. Cole Advisors Inc. now owns 6,018 shares of the company’s stock worth $1,674,000 after purchasing an additional 1,987 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Cencora in the 1st quarter worth approximately $753,000. Close Asset Management Ltd acquired a new position in shares of Cencora during the 1st quarter worth approximately $110,629,000. Finally, Advisors Preferred LLC purchased a new stake in shares of Cencora in the first quarter valued at approximately $725,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.2%

NYSE COR opened at $360.79 on Thursday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The stock has a market capitalization of $69.95 billion, a P/E ratio of 37.12, a PEG ratio of 1.56 and a beta of 0.63. The firm’s 50-day moving average is $325.26 and its two-hundred day moving average is $303.65. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $369.00.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same period last year, the business earned $3.34 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 46,640 shares of company stock worth $14,099,338 over the last 90 days. 10.80% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.